UBE2L3, a Partner of MuRF1/TRIM63, Is Involved in the Degradation of Myofibrillar Actin and Myosin.
Actins
/ metabolism
Animals
Cell Line
Dexamethasone
/ pharmacology
Histocompatibility Antigens Class II
/ metabolism
Male
Mice
Mice, Inbred C57BL
Muscle Fibers, Skeletal
/ cytology
Muscle Proteins
/ metabolism
Muscular Atrophy
/ metabolism
Protein Binding
RNA Interference
RNA, Small Interfering
/ metabolism
Tripartite Motif Proteins
/ metabolism
Ubiquitin-Conjugating Enzymes
/ antagonists & inhibitors
Ubiquitin-Protein Ligases
/ metabolism
MicroScale-Thermophoresis
MuRF1/TRIM63
UBE2L3/UbcH7
alpha-actin
contractile proteins
glucocorticoids
myosin
skeletal muscle atrophy
ubiquitinating enzymes
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
03 08 2021
03 08 2021
Historique:
received:
31
03
2021
revised:
21
07
2021
accepted:
28
07
2021
entrez:
27
8
2021
pubmed:
28
8
2021
medline:
18
11
2021
Statut:
epublish
Résumé
The ubiquitin proteasome system (UPS) is the main player of skeletal muscle wasting, a common characteristic of many diseases (cancer, etc.) that negatively impacts treatment and life prognosis. Within the UPS, the E3 ligase MuRF1/TRIM63 targets for degradation several myofibrillar proteins, including the main contractile proteins alpha-actin and myosin heavy chain (MHC). We previously identified five E2 ubiquitin-conjugating enzymes interacting with MuRF1, including UBE2L3/UbcH7, that exhibited a high affinity for MuRF1 (K
Identifiants
pubmed: 34440743
pii: cells10081974
doi: 10.3390/cells10081974
pmc: PMC8392593
pii:
doi:
Substances chimiques
Actins
0
Histocompatibility Antigens Class II
0
Muscle Proteins
0
RNA, Small Interfering
0
Tripartite Motif Proteins
0
Dexamethasone
7S5I7G3JQL
Ube2l3 protein, mouse
EC 2.3.2.23
Ubiquitin-Conjugating Enzymes
EC 2.3.2.23
Trim63 protein, mouse
EC 2.3.2.27
Ubiquitin-Protein Ligases
EC 2.3.2.27
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Association Française contre les Myopathies
ID : #19521
Organisme : Fondation pour la Recherche Médicale
ID : DEQ20180339180
Organisme : French government IDEX-ISITE initiative CAP 20e25
ID : 16-IDEX-0001
Organisme : European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement
ID : No 813599
Références
Proc Natl Acad Sci U S A. 2014 Dec 9;111(49):17456-61
pubmed: 25422456
J Physiol. 2011 Oct 1;589(Pt 19):4759-76
pubmed: 21807613
FASEB J. 2011 Nov;25(11):3790-802
pubmed: 21764995
Nature. 2011 Jun 2;474(7349):105-8
pubmed: 21532592
Biochem J. 2016 Oct 15;473(20):3401-3419
pubmed: 27729585
Cell. 2010 Aug 20;142(4):531-43
pubmed: 20723755
Molecules. 2021 Jan 14;26(2):
pubmed: 33466753
Science. 2001 Nov 23;294(5547):1704-8
pubmed: 11679633
Nat Genet. 2010 Dec;42(12):1118-25
pubmed: 21102463
J Clin Invest. 2007 Sep;117(9):2486-95
pubmed: 17786241
J Biol Chem. 1999 Oct 29;274(44):31707-12
pubmed: 10531381
J Cachexia Sarcopenia Muscle. 2010 Sep;1(1):1-5
pubmed: 21475699
Nature. 2013 Nov 21;503(7476):422-426
pubmed: 24141947
Int J Mol Sci. 2020 Jun 30;21(13):
pubmed: 32630118
Int J Mol Sci. 2020 May 23;21(10):
pubmed: 32456262
J Cell Sci. 2014 Aug 1;127(Pt 15):3280-93
pubmed: 24906799
Nat Rev Cancer. 2011 Oct 24;11(11):812-23
pubmed: 22020207
Cell. 2000 Aug 18;102(4):533-9
pubmed: 10966114
Mol Cell Biol. 2009 Sep;29(17):4798-811
pubmed: 19546233
EMBO J. 2012 Aug 1;31(15):3334-50
pubmed: 22773186
J Cell Sci. 2014 Aug 15;127(Pt 16):3488-504
pubmed: 24928900
J Biol Chem. 1990 May 25;265(15):8550-7
pubmed: 2187867
Int J Biochem Cell Biol. 2016 Oct;79:488-493
pubmed: 27378730
J Cachexia Sarcopenia Muscle. 2016 Dec;7(5):507-509
pubmed: 27891294
Cell. 2010 Nov 24;143(5):677-81
pubmed: 21111228
Proc Natl Acad Sci U S A. 2004 Dec 28;101(52):18135-40
pubmed: 15601779
Elife. 2020 Jun 23;9:
pubmed: 32573437
Sports (Basel). 2020 Jan 10;8(1):
pubmed: 31936810
Nat Genet. 2012 Dec;44(12):1341-8
pubmed: 23143594
FASEB J. 2004 Jan;18(1):39-51
pubmed: 14718385
FASEB J. 2004 Mar;18(3):522-4
pubmed: 14715702
Assay Drug Dev Technol. 2011 Aug;9(4):342-53
pubmed: 21812660
Mol Cell. 2009 Dec 11;36(5):831-44
pubmed: 20005846
Mol Biol Cell. 2009 Jan;20(1):1-9
pubmed: 18946090
Am J Physiol Cell Physiol. 2018 Jun 1;314(6):C721-C731
pubmed: 29513566
Genes Immun. 2012 Jul;13(5):380-7
pubmed: 22476155
Nature. 2018 Apr;556(7701):381-385
pubmed: 29643511
Arthritis Res Ther. 2020 Apr 25;22(1):93
pubmed: 32334614
J Biol Chem. 2014 Aug 8;289(32):21909-25
pubmed: 24891504
Biochimie. 2019 Nov;166:251-269
pubmed: 31325479
Cell Div. 2009 Aug 07;4:17
pubmed: 19664228
J Biol Chem. 2017 Apr 7;292(14):5992-6003
pubmed: 28255090
J Biomed Biotechnol. 2010;2010:693741
pubmed: 20625437
Int J Mol Sci. 2020 Sep 11;21(18):
pubmed: 32933049
Nat Chem Biol. 2016 May;12(5):324-31
pubmed: 26928937
J Clin Invest. 1997 Jul 1;100(1):197-203
pubmed: 9202072
Proc Natl Acad Sci U S A. 2017 Feb 21;114(8):E1375-E1384
pubmed: 28096335
J Virol. 2004 May;78(10):5338-46
pubmed: 15113913
Nat Genet. 2009 Nov;41(11):1234-7
pubmed: 19838193
Cell Res. 2016 Apr;26(4):423-40
pubmed: 27002219
J Biol Chem. 1996 Oct 25;271(43):26690-7
pubmed: 8900146
Cells. 2018 Dec 04;7(12):
pubmed: 30518141
J Cell Biol. 2009 Jun 15;185(6):1083-95
pubmed: 19506036
J Cachexia Sarcopenia Muscle. 2018 Feb;9(1):129-145
pubmed: 29271608
FASEB J. 2019 Jan;33(1):1235-1247
pubmed: 30113882
Nat Cell Biol. 2009 Feb;11(2):123-32
pubmed: 19136968
Cell Metab. 2007 Nov;6(5):376-85
pubmed: 17983583
Mol Cell Biol. 2014 Apr;34(7):1322-35
pubmed: 24469399
Skelet Muscle. 2019 Sep 14;9(1):24
pubmed: 31521204
Am J Physiol Cell Physiol. 2018 Aug 1;315(2):C164-C185
pubmed: 29561660
Nat Commun. 2010 Oct 19;1:100
pubmed: 20981028
J Biol Chem. 2011 Jun 17;286(24):21277-86
pubmed: 21518764
Curr Opin Rheumatol. 2006 Nov;18(6):631-5
pubmed: 17053511